<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39434214</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Humoral and cellular immune response to AZD1222 /Covishield and BV152/Covaxin COVID-19 vaccines among adults in India.</ArticleTitle><Pagination><StartPage>2410579</StartPage><MedlinePgn>2410579</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2410579</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2024.2410579</ELocationID><Abstract><AbstractText>Several COVID-19 vaccines were developed using different approaches to prevent both symptomatic COVID-19 cases and fatalities. The adults were vaccinated with two doses of AZD1222/Covishield (<i>n</i> = 77) [manufactured by Serum Institute of India Pvt Ltd] vaccine and BV152/Covaxin (<i>n</i> = 99) [manufactured by Bharat Biotech] vaccine. They were assessed for immune response at pre-vaccination, 1 month post first and 6 months post second dose for anti-SARS-CoV-2 IgG antibody, surrogate neutralizing antibody (NAbs), immune phenotypes, antigen specific NK, B and T cell response, their effector functionality by ELISPOT and plasma cytokine profile. Both vaccines elicited enhanced IgG antibody and Nab levels compared to the baseline. BV152/Covaxin, the whole virus inactivated vaccine exhibited higher IgG (70% vs 100%), Nab (90% vs 100%), and robust T cell (31% vs 96%) responses at 6 months post second dose compared to 1 month post first dose justifying the utility of the second dose. Detection of SARS-CoV-2 WV and S1 specific CD4+ central T cell memory response in AZD1222/Covishield vaccinee at 6 months post second dose and higher CD4+ and CD8+ naïve and central memory T cell response in BV152/Covaxin vaccinee at 1 month post first dose indicated the involvement of memory T cells. Persistent IgG and NAb responses along with IgG+B and IgG+memory B cells in AZD1222/Covishield recipients at 6 months post second dose indicated sustained immune memory response. Continued heightened IFN-γ secreting T cell response (ELISPOT) displayed by both the vaccine platforms could serve as a co correlate of protection, further to evaluation in follow up studies. Overall, our data suggest that coordinated functions of humoral and cellular branches of adaptive immunity may pave ways toward protective immunity against COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tripathy</LastName><ForeName>Anuradha S</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0002-8919-3819</Identifier><AffiliationInfo><Affiliation>ICMR-National Institute of Virology, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Dharmendra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>ICMR-National Institute of Virology, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trimbake</LastName><ForeName>Diptee</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>ICMR-National Institute of Virology, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salwe</LastName><ForeName>Sukeshani</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ICMR-National Institute of Virology, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripathy</LastName><ForeName>Srikanth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dr. D. Y. Patil Medical College, Hospital &amp; Research Centre, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakrani</LastName><ForeName>Arjun</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dr. D. Y. Patil Medical College, Hospital &amp; Research Centre, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jali</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dr. D. Y. Patil Medical College, Hospital &amp; Research Centre, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chavan</LastName><ForeName>Hanmant</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Dr. D. Y. Patil Medical College, Hospital &amp; Research Centre, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadav</LastName><ForeName>Pragya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>ICMR-National Institute of Virology, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahay</LastName><ForeName>Rima</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ICMR-National Institute of Virology, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarje</LastName><ForeName>Prakash</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>ICMR-National Institute of Virology, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babar</LastName><ForeName>Prasad</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>ICMR-National Institute of Virology, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shete</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ICMR-National Institute of Virology, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nandapurkar</LastName><ForeName>Ashok</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Aundh Chest Hospital, Pune, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulkarni</LastName><ForeName>Milind</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Aundh Chest Hospital, Pune, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>76JZE5DSN6</RegistryNumber><NameOfSubstance UI="C000722386">BBV152 COVID-19 vaccine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="Y">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="Y">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AZD1222/Covishield</Keyword><Keyword MajorTopicYN="N">BV152/Covaxin</Keyword><Keyword MajorTopicYN="N">SARS CoV-2 specific IgG and “Neutralizing antibodies”</Keyword><Keyword MajorTopicYN="N">longitudinal follow-up at 6 months post second dose</Keyword><Keyword MajorTopicYN="N">“B-lymphocytes memory”</Keyword><Keyword MajorTopicYN="N">“T cell response”</Keyword><Keyword MajorTopicYN="N">“T-lymphocytes memory”</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39434214</ArticleId><ArticleId IdType="pmc">PMC11497953</ArticleId><ArticleId IdType="doi">10.1080/21645515.2024.2410579</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allam Z. Chapter 1 - The first 50 days of COVID-19: a detailed chronological timeline and extensive review of literature documenting the pandemic. In: Surveying the COVID-19 pandemic and its implications. 2020. p. 1. doi:10.1016/B978-0-12-824313-8.00001-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-824313-8.00001-2</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Public Health Emergency of International Concern (PHEIC) . Global research and innovation forum: COVID-19 public health emergency of international concern (PHEIC) global research and innovation forum (who.Int).</Citation></Reference><Reference><Citation>Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Bio Medica: Atenei Parmensis. 2020;91(1):157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui AF, Wiederkehr M, Rozanova L, Flahault A. Situation of India in the COVID-19 pandemic: India’s initial pandemic experience. Int J Environ Res Public Health. 2020. Dec. 17(23):8994. doi:10.3390/ijerph17238994.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17238994</ArticleId><ArticleId IdType="pmc">PMC7730885</ArticleId><ArticleId IdType="pubmed">33276678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang D, Chang X, He Y, Tan KJ. The determinants of COVID-19 morbidity and mortality across countries. Sci Rep. 2022. Apr 7. 12(1):5888. doi:10.1038/s41598-022-09783-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-09783-9</ArticleId><ArticleId IdType="pmc">PMC8989117</ArticleId><ArticleId IdType="pubmed">35393471</ArticleId></ArticleIdList></Reference><Reference><Citation>Tendulkar P, Pandey P, Panda PK, Bhadoria AS, Kulshreshtha P, Mishra M, Saxena G. Comparative study between the first and second wave of COVID-19 deaths in India: a single center study. Cureus. 2023. Apr. 15(4). doi:10.7759/cureus.37472.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.37472</ArticleId><ArticleId IdType="pmc">PMC10176533</ArticleId><ArticleId IdType="pubmed">37187656</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande GR, Bhukya PL, Yadav PD, Salunke A, Patil C, Tilekar BN, Rakhe A, Srivastava R, Gurav YK, Potdar V, et al. Comparison of neutralizing antibody response in first and second waves of SARS-CoV-2 pandemic in India. J Travel Med. 2022. Apr;29(3):taab196. doi:10.1093/jtm/taab196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/taab196</ArticleId><ArticleId IdType="pmc">PMC8807193</ArticleId><ArticleId IdType="pubmed">34963131</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary OP, Singh I, Rodriguez-Morales AJ. Second wave of COVID-19 in India: dissection of the causes and lessons learnt. Travel Med Infect Dis. 2021. Sep;43:102126. doi:10.1016/j.tmaid.2021.102126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2021.102126</ArticleId><ArticleId IdType="pmc">PMC8214078</ArticleId><ArticleId IdType="pubmed">34144178</ArticleId></ArticleIdList></Reference><Reference><Citation>Kar SK, Ransing R, Arafat SY, Menon V. Second wave of COVID-19 pandemic in India: barriers to effective governmental response. EClinicalMedicine. 2021. June 1;36:100915. doi:10.1016/j.eclinm.2021.100915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100915</ArticleId><ArticleId IdType="pmc">PMC8164526</ArticleId><ArticleId IdType="pubmed">34095794</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan M, Sharma A, Priyanka N, Thakur N, Rajkhowa TK, Choudhary OP. Delta variant (B. 1.617. 2) of SARS-CoV-2: mutations, impact, challenges and possible solutions. Hum Vaccines &amp; Immunother. 2022. Nov 30;18(5):2068883. doi:10.1080/21645515.2022.2068883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2068883</ArticleId><ArticleId IdType="pmc">PMC9359381</ArticleId><ArticleId IdType="pubmed">35507895</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett BJ, Grove J, MacLean OA, Wilkie C, De Lorenzo G, Furnon W, Cantoni D, Scott S, Logan N, Ashraf S, et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat Microbiol. 2022. Aug;7(8):1161–15. doi:10.1038/s41564-022-01143-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01143-7</ArticleId><ArticleId IdType="pmc">PMC9352574</ArticleId><ArticleId IdType="pubmed">35798890</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav PD, Sahay RR, Salwe S, Trimbake D, Babar P, Sapkal GN, Deshpande GR, Bhise K, Shete AM, Abraham P, et al. Broadly reactive sars‐CoV‐2‐specific T‐cell response and participation of memory B and T cells in patients with omicron COVID‐19 infection. J Immunol Res. 2023;2023(1):8846953. doi:10.1155/2023/8846953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2023/8846953</ArticleId><ArticleId IdType="pmc">PMC10597734</ArticleId><ArticleId IdType="pubmed">37881339</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 Omicron variant: recent progress and future perspectives. Signal transduction and targeted therapy. Signal Transduct Targeted Ther. 2022. Apr 28;7(1):1–1. doi:10.1038/s41392-022-00997-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00997-x</ArticleId><ArticleId IdType="pmc">PMC9047469</ArticleId><ArticleId IdType="pubmed">35484110</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar P, Banerjee S, Saha SA, Mitra P, Sarkar S. Genome surveillance of SARS-CoV-2 variants and their role in pathogenesis focusing on second wave of COVID-19 in India. Sci Rep. 2023. Mar 22;13(1):4692. doi:10.1038/s41598-023-30815-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-30815-5</ArticleId><ArticleId IdType="pmc">PMC10031706</ArticleId><ArticleId IdType="pubmed">36949118</ArticleId></ArticleIdList></Reference><Reference><Citation>Barouch DH. Covid-19 vaccines—immunity, variants, boosters. N Engl J Med. 2022. Sep 15;387(11):1011–1020. doi:10.1056/NEJMra2206573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2206573</ArticleId><ArticleId IdType="pmc">PMC9454645</ArticleId><ArticleId IdType="pubmed">36044620</ArticleId></ArticleIdList></Reference><Reference><Citation>COWIN dashboard . [accessed 2024 Feb
29]. https://dashboard.cowin.gov.in/.</Citation></Reference><Reference><Citation>Bagcchi S. The world’s largest COVID-19 vaccination campaign. Lancet: Infect Dis. 2021. Mar;21(3):323. doi:10.1016/S1473-3099(21)00081-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00081-5</ArticleId><ArticleId IdType="pmc">PMC7906682</ArticleId><ArticleId IdType="pubmed">33639124</ArticleId></ArticleIdList></Reference><Reference><Citation>Malabadi RB, Meti NT, Chalannavar RK. Applications of nanotechnology in vaccine development for coronavirus (SARS-CoV-2) disease (Covid-19). Int J Res Sci Innovations. 2021;8(2):191–198. doi:10.51244/IJRSI.2021.8312.</Citation><ArticleIdList><ArticleId IdType="doi">10.51244/IJRSI.2021.8312</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Phatak SR, Singh R, Bhattacharjee K, Singh NK, Gupta A, Sharma A. Antibody response after first and second-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) among health care workers in India: the final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. Vaccine. 2021. Oct 22;39(44):6492–6509. doi:10.1016/j.vaccine.2021.09.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.09.055</ArticleId><ArticleId IdType="pmc">PMC8461292</ArticleId><ArticleId IdType="pubmed">34600747</ArticleId></ArticleIdList></Reference><Reference><Citation>HFW_DCGI_energency_use_authorisation_03012021_2.pdf (icmr.gov.in) .</Citation></Reference><Reference><Citation>Thiagarajan K. What do we know about India’s Covaxin vaccine? BMJ: Br Med J (Online). 2021. Apr 20;373:n997. doi:10.1136/bmj.n997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n997</ArticleId><ArticleId IdType="pubmed">33879478</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S, Kar SS, Samanta S, Banerjee J, Giri B, Dash SK. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. Immunologic Res. 2022. June;70(3):289–315. doi:10.1007/s12026-022-09265-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-022-09265-0</ArticleId><ArticleId IdType="pmc">PMC8861611</ArticleId><ArticleId IdType="pubmed">35192185</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapkal G, Yadav PD, Ella R, Abraham P, Patil DY, Gupta N, Panda S, Mohan VK, Bhargava B. Neutralization of VUI B.1.1. 28 P2 variant with sera of COVID-19 recovered cases and recipients of Covaxin an inactivated COVID-19 vaccine. J Travel Med. 2021. Oct;28(7):taab077. doi:10.1093/jtm/taab077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/taab077</ArticleId><ArticleId IdType="pmc">PMC8194512</ArticleId><ArticleId IdType="pubmed">34002240</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapkal GN, Yadav PD, Ella R, Deshpande GR, Sahay RR, Gupta N, Vadrevu KM, Abraham P, Panda S, Bhargava B. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B. 1.1. 7 variant of SARS-CoV-2. J Travel Med. 2021. May;28(4):taab051. doi:10.1093/jtm/taab051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/taab051</ArticleId><ArticleId IdType="pmc">PMC8083765</ArticleId><ArticleId IdType="pubmed">33772577</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav PD, Sapkal GN, Abraham P, Deshpande G, Nyayanit DA, Patil DY, Gupta N, Sahay RR, Shete AM, Kumar S, et al. Neutralization potential of Covishield vaccinated individuals sera against B. 1.617. 1. Clin Infect Dis. 2022. Feb 1;74(3):558–559. doi:10.1093/cid/ciab483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab483</ArticleId><ArticleId IdType="pubmed">34036309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, Das D, Raju D, Praturi U, Sapkal G, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021. Jul 1;21(7):950–961. doi:10.1016/S1473-3099(21)00070-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00070-0</ArticleId><ArticleId IdType="pmc">PMC8221739</ArticleId><ArticleId IdType="pubmed">33705727</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, Halkerston R, Hill J, Jenkin D, Stockdale L, et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021. Feb;27(2):279–288. doi:10.1038/s41591-020-01179-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01179-4</ArticleId><ArticleId IdType="pubmed">33335322</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–897. doi:10.1016/S0140-6736(20)31866-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31866-3</ArticleId><ArticleId IdType="pmc">PMC7471804</ArticleId><ArticleId IdType="pubmed">32896291</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni PS, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P, Garg BS, Gogtay NJ, Tambe M, Lalwani S, et al. A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. EClinicalMedicine. 2021. Dec 1;42:101218. doi:10.1016/j.eclinm.2021.101218.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101218</ArticleId><ArticleId IdType="pmc">PMC8629682</ArticleId><ArticleId IdType="pubmed">34870133</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas RE, Sukumaran A, Krishnan RA, Thomas T, Edwin BT, Haritha PR, Varghese BM, Paul JK, Kumar CSS, Vasudevan DM. Impact of covishield vaccination in terms of SARS CoV-2 neutralizing antibody expression. Indian J Clin Biochem. 2023. Jan;38(1):51–58. doi:10.1007/s12291-022-01030-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12291-022-01030-2</ArticleId><ArticleId IdType="pmc">PMC9012865</ArticleId><ArticleId IdType="pubmed">35465605</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanda R, Gupta P, Giri AK, Patel S, Shah S, Mohapatra E. Serological evaluation of antibody titers after vaccination against COVID-19 in 18-44-year-old individuals at a tertiary care center. Cureus. 2023. June;15(6). doi:10.7759/cureus.40543.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.40543</ArticleId><ArticleId IdType="pmc">PMC10350605</ArticleId><ArticleId IdType="pubmed">37465786</ArticleId></ArticleIdList></Reference><Reference><Citation>Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020. Aug 15;396(10249):467–478. doi:10.1016/S0140-6736(20)31604-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31604-4</ArticleId><ArticleId IdType="pmc">PMC7445431</ArticleId><ArticleId IdType="pubmed">32702298</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav PD, Sapkal GN, Sahay RR, Patil DY, Agrawal S, Adsul B, Tripathy S, Deshpande GR, Nyayanit DA, Shete AM, et al. Reduced neutralizing antibody response in naïve Covishield vaccinees against Omicron emphasizes booster vaccination. J Infect. 2022. Jul;85(1):90. doi:10.1016/j.jinf.2022.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.04.031</ArticleId><ArticleId IdType="pmc">PMC9021040</ArticleId><ArticleId IdType="pubmed">35461911</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeewandara C, Kamaladasa A, Pushpakumara PD, Jayathilaka D, Aberathna IS, Danasekara DR, Guruge D, Ranasinghe T, Dayarathna S, Pathmanathan T, et al. Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers. Nat Commun. 2021. Jul 29;12(1):4617. doi:10.1038/s41467-021-24579-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24579-7</ArticleId><ArticleId IdType="pmc">PMC8322137</ArticleId><ArticleId IdType="pubmed">34326317</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021. Jan 9;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Abebe EC, Dejenie TA. Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. Front Immunol. 2023;14:1055457. doi:10.3389/fimmu.2023.1055457.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1055457</ArticleId><ArticleId IdType="pmc">PMC9892939</ArticleId><ArticleId IdType="pubmed">36742320</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022. Feb;23(2):186–193. doi:10.1038/s41590-021-01122-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01122-w</ArticleId><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoun E, Peng Y, Dong T. Vaccine-induced CD8+ T cells are key to protection from SARS-CoV-2. Nat Immunol. 2023. Oct;24(10):1594–1596. doi:10.1038/s41590-023-01621-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01621-y</ArticleId><ArticleId IdType="pubmed">37735590</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathy AS, Trimbake D, Suryawanshi PV, Tripathy SP, Gurav YK, Potdar VA, Chaudhary ML, Athavale P, Mokashi ND, Patsute SD, et al. Peripheral lymphocyte subset alteration in patients with COVID-19 having differential clinical manifestations. Indian J Med Res. 2022. Jan 1;155(1):136–147. doi:10.4103/ijmr.IJMR_453_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmr.IJMR_453_21</ArticleId><ArticleId IdType="pmc">PMC9552374</ArticleId><ArticleId IdType="pubmed">35859440</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanapati S, Das R, Tripathy AS. Phenotypic and functional analyses of NK and NKT-like populations during the early stages of chikungunya infection. Front Microbiol. 2015. Sep 1;6:895. doi:10.3389/fmicb.2015.00895.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2015.00895</ArticleId><ArticleId IdType="pmc">PMC4555083</ArticleId><ArticleId IdType="pubmed">26388848</ArticleId></ArticleIdList></Reference><Reference><Citation>Tripathy AS, Vishwakarma S, Trimbake D, Gurav YK, Potdar VA, Mokashi ND, Patsute SD, Kaushal H, Choudhary ML, Tilekar BN, et al. Pro-inflammatory CXCL-10, tnf-α, IL-1β, and IL-6: biomarkers of SARS-CoV-2 infection. Archiv Virol. 2021. Dec;166(12):3301–3310. doi:10.1007/s00705-021-05247-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-021-05247-z</ArticleId><ArticleId IdType="pmc">PMC8459145</ArticleId><ArticleId IdType="pubmed">34554303</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash GC, Subhadra S, Turuk J, Parai D, Rath S, Sabat J, Rout UK, Kanungo S, Choudhary HR, Nanda RR, et al. Breakthrough sars‐CoV‐2 infections among BBV‐152 (COVAXIN®) and AZD1222 (COVISHIELDTM) recipients: report from the eastern state of India. J Med Virol. 2022. Mar;94(3):1201–1205. doi:10.1002/jmv.27382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27382</ArticleId><ArticleId IdType="pmc">PMC8661601</ArticleId><ArticleId IdType="pubmed">34622961</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahay RR, Yadav PD, Nandapurkar A, Dhawde R, Suryawanshi A, Patil DY, Shete AM, Sapkal GN, Kulkarni M, Gurav YK, et al. Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, covaxin after six months. Hum Vaccines &amp; Immunother. 2022. Dec 30;18(7):2156753. doi:10.1080/21645515.2022.2156753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2156753</ArticleId><ArticleId IdType="pmc">PMC9891675</ArticleId><ArticleId IdType="pubmed">36576223</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande GR, Yadav PD, Abraham P, Nyayanit DA, Sapkal GN, Shete AM, Gupta N, Vadrevu KM, Ella R, Panda S, et al. Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against alpha, beta, delta and omicron variants of concern. J Travel Med. 2022;29(3):p.taac039. doi:10.1093/jtm/taac039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/taac039</ArticleId><ArticleId IdType="pubmed">35325176</ArticleId></ArticleIdList></Reference><Reference><Citation>Satpathy PS, Endow S, Gantait K, Chand PH, Jaiswal A, Jana B, Kundu P, Ghosh T. Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India. Iran J Microbiol. 2022. Oct;14(5):611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9723424</ArticleId><ArticleId IdType="pubmed">36531814</ArticleId></ArticleIdList></Reference><Reference><Citation>Vikkurthi R, Ansari A, Pai AR, Jha SN, Sachan S, Pandit S, Nikam B, Kalia A, Jit BP, Parray HA, et al. Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern. Nat Microbiol. 2022. Jul;7(7):974–985. doi:10.1038/s41564-022-01161-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01161-5</ArticleId><ArticleId IdType="pubmed">35681012</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Cheng L, Li J, Wang X, Wang F, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020. June;26(6):842–844. doi:10.1038/s41591-020-0901-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0901-9</ArticleId><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O, Baxter AE, Herati RS, Oldridge DA, Gouma S, et al. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity. 2021. Sep 14;54(9):2133–2142.e3. doi:10.1016/j.immuni.2021.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.08.001</ArticleId><ArticleId IdType="pmc">PMC8361141</ArticleId><ArticleId IdType="pubmed">34453880</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, Flaxman A, Wright D, Bellamy D, Bittaye M, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021. Feb;27(2):270–278. doi:10.1038/s41591-020-01194-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01194-5</ArticleId><ArticleId IdType="pubmed">33335323</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa Duque JS, Wang X, Leung D, Cheng SM, Cohen CA, Mu X, Hachim A, Zhang Y, Chan SM, Chaothai S, et al. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. Nat Commun. 2022. June 28;13(1):3700. doi:10.1038/s41467-022-31485-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31485-z</ArticleId><ArticleId IdType="pmc">PMC9240007</ArticleId><ArticleId IdType="pubmed">35764637</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Chen W, Li J, Chen M, Li Q, Lv M, Zhou S, Bai S, Wang Y, Zhang L, et al. Status of humoral and cellular immune responses within 12 months following CoronaVac vaccination against COVID-19. MBio. 2022. June 28;13(3):e00181–e00122. doi:10.1128/mbio.00181-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.00181-22</ArticleId><ArticleId IdType="pmc">PMC9239277</ArticleId><ArticleId IdType="pubmed">35475648</ArticleId></ArticleIdList></Reference><Reference><Citation>Asokan MS, Joan RF, Babji S, Dayma G, Nadukkandy P, Subrahmanyam V, Pandey A, Malagi G, Arya P, Mahajan V, et al. Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study. Lancet Reg Health-Southeast Asia. 2024;22:100361. doi:10.1016/j.lansea.2024.100361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lansea.2024.100361</ArticleId><ArticleId IdType="pmc">PMC10934322</ArticleId><ArticleId IdType="pubmed">38482152</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wu DI, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investigation. 2020. May 1;130(5):2620–2629. doi:10.1172/JCI137244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI137244</ArticleId><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingeswaran M, Goyal T, Ghosh R, Suri S, Mitra P, Misra S, Sharma P. Inflammation, immunity and immunogenetics in COVID-19: a narrative review. Indian J Clin Biochem. 2020. Jul;35(3):260–273. doi:10.1007/s12291-020-00897-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12291-020-00897-3</ArticleId><ArticleId IdType="pmc">PMC7275846</ArticleId><ArticleId IdType="pubmed">32641873</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Li W, Tong Q, Yi J, Zhao L, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020. May 1;55:102763. doi:10.1016/j.ebiom.2020.102763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102763</ArticleId><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>Safont G, Villar-Hernández R, Smalchuk D, Stojanovic Z, Marín A, Lacoma A, Pérez-Cano C, López-Martínez A, Molina-Moya B, Solis AJ, et al. Measurement of ifn-γ and IL-2 for the assessment of the cellular immunity against SARS-CoV-2. Sci Rep. 2024. Jan 11;14(1):1137. doi:10.1038/s41598-024-51505-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-51505-w</ArticleId><ArticleId IdType="pmc">PMC10784529</ArticleId><ArticleId IdType="pubmed">38212416</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Yuen TT, Dou Y, Hu J, Li R, Zeng Z, Lin X, Gong H, Chan CH, Yoon C, et al. Vaccine-induced protection against SARS-CoV-2 requires ifn-γ-driven cellular immune response. Nat Commun. 2023. June 10;14(1):3440. doi:10.1038/s41467-023-39096-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-39096-y</ArticleId><ArticleId IdType="pmc">PMC10257169</ArticleId><ArticleId IdType="pubmed">37301910</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, Aiano F, Amin-Chowdhury Z, Hoschler K, Brooks T, et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol. 2021. May. 22(5):620–626. doi:10.1038/s41590-021-00902-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00902-8</ArticleId><ArticleId IdType="pmc">PMC7610739</ArticleId><ArticleId IdType="pubmed">33674800</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao C, Jiang J, Liu M, Dai Y, Chang T, Ji T, Gong F. Longitudinal evaluation of innate immune responses to three doses of CoronaVac vaccine. Front Immunol. 2023. Oct 2;14:1277831. doi:10.3389/fimmu.2023.1277831.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1277831</ArticleId><ArticleId IdType="pmc">PMC10577214</ArticleId><ArticleId IdType="pubmed">37849746</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryawanshi P, Patil‐Takbhate B, Athavale P, Mirza S, Tripathy A, Kanitkar S, Shivnitwar S, Barthwal MS, Dole S, Chavan H, et al. T‐cell responses in COVID‐19 survivors 6− 8 months after infection: a longitudinal cohort study in Pune. Immun, Inflammation Dis. 2024. June;12(6):e1238. doi:10.1002/iid3.1238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.1238</ArticleId><ArticleId IdType="pmc">PMC11165687</ArticleId><ArticleId IdType="pubmed">38860770</ArticleId></ArticleIdList></Reference><Reference><Citation>Arankalle V, Kulkarni-Munje A, Kulkarni R, Palkar S, Patil R, Oswal J, Lalwani S, Mishra AC. Immunogenicity of two COVID-19 vaccines used in India: an observational cohort study in health care workers from a tertiary care hospital. Front Immunol. 2022. Sep 23;13:928501. doi:10.3389/fimmu.2022.928501.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.928501</ArticleId><ArticleId IdType="pmc">PMC9540493</ArticleId><ArticleId IdType="pubmed">36211366</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryawanshi P, Takbhate B, Athavale P, Jali P, Memane N, Mirza S, Karandikar M, Kakrani AL, Kanitkar S, Gandham N, et al. Lymphopenia with altered T cell subsets in hospitalized COVID-19 patients in Pune, India. Viral Immunol. 2023. Apr 1;36(3):163–175. doi:10.1089/vim.2022.0123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2022.0123</ArticleId><ArticleId IdType="pubmed">36897333</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahluwalia P, Vaibhav K, Ahluwalia M, Mondal AK, Sahajpal N, Rojiani AM, Kolhe R. Infection and immune memory: variables in robust protection by vaccines against SARS-CoV-2. Front Immunol. 2021. May 11;12:660019. doi:10.3389/fimmu.2021.660019.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.660019</ArticleId><ArticleId IdType="pmc">PMC8144450</ArticleId><ArticleId IdType="pubmed">34046033</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA, Kedl RM. T cell responses: naive to memory and everything in between. Adv Physiol Educ. 2013. Dec;37(4):273–283. doi:10.1152/advan.00066.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/advan.00066.2013</ArticleId><ArticleId IdType="pmc">PMC4089090</ArticleId><ArticleId IdType="pubmed">24292902</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavukcuoglu E, Yanik H, Parveen M, Uluturk S, Durusu-Tanriover M, Inkaya AC, Akova M, Unal S, Esendagli G. Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination. Sci Rep. 2023. Mar 21;13(1):4610. doi:10.1038/s41598-023-31347-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-31347-8</ArticleId><ArticleId IdType="pmc">PMC10028771</ArticleId><ArticleId IdType="pubmed">36944716</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar NP, Banurekha VV, Cp GK, Nancy A, Padmapriyadarsini C, Mary AS, Devi KU, Murhekar M, Babu S. Prime-boost vaccination with Covaxin/BBV152 induces heightened systemic cytokine and chemokine responses. Front Immunol. 2021. Oct 15;12:752397. doi:10.3389/fimmu.2021.752397.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.752397</ArticleId><ArticleId IdType="pmc">PMC8554328</ArticleId><ArticleId IdType="pubmed">34721425</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>